A CD38 / CD3xCD28 trispecific T‐cell engager as a potentially active agent in multiple myeloma patients relapsed and/or refractory to anti‐ CD38 monoclonal antibodies
British Journal of Haematology · 2024-12 · 205 (6) · 2262-2267
DOI: 10.1111/bjh.19784 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 22.09.2024. Verfasst von Aintzane Zabaleta und 11 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Center Clinica Universidad de Navarra (CCUN), Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra …. Hauptthemen laut MEDLINE: Multiple Myeloma, ADP-ribosyl Cyclase 1, T-Lymphocytes. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Scientific Foundation of the Spanish Association Against Cancer, Instituto de Salud Carlos III, Sanofi.
Abstract (Originalsprache)
There is accumulating evidence of BCMA and GPRC5D loss after treatment with T‐cell redirecting therapies in patients with relapsed/refractory multiple myeloma (RRMM). While complete CD38 loss is not observed upon relapses after treatment with anti‐CD38 monoclonal antibodies (mAb), there is downregulation of surface CD38 expression and decreased number and function of NK cells, which renders these patients resistant to retreatment with anti‐CD38 mAb. Here, we provide preclinical evidence that RRMM patients previously exposed to anti‐CD38 mAb could benefit from T‐cell‐based immunotherapy that depend less on CD38 antigen density and NK‐cell activity, such as the novel CD38/CD3xCD28 trispecific T‐cell engager, SAR442257.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Center Clinica Universidad de Navarra (CCUN), Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IdiSNA), CIBER-ONC Numbers CB16/12/00369 and CB16/12/00489, Pamplona,…
- Sanofi R&D, Cambridge, Massachusetts, USA.
ORCID-Profile: Luis-Esteban Tamariz-Amador, Paula Rodriguez-Otero, Jesús San-Miguel, Esperanza Martín-Sánchez
Förderung
- Scientific Foundation of the Spanish Association Against Cancer
- Instituto de Salud Carlos III
- Sanofi
- Centro de Investigación Biomédica en Red - Área de Oncología - del Instituto de Salud Carlos III (CIBERONC)
- University of Navarra
- Airc_Accelerator Award Program
- Cancer Research UK
- Centro de Investigación Biomédica en Red de Cáncer
Zitieren
APA
Zabaleta, A., Blanco, L., Kim, P. S., Bisht, K., Wang, H., Van de Velde, H., Lasa, M., Tamariz-Amador, L. E., Rodriguez-Otero, P., San-Miguel, J., Paiva, B., & Martín-Sánchez, E. (2024). A CD38 / CD3xCD28 trispecific T‐cell engager as a potentially active agent in multiple myeloma patients relapsed and/or refractory to anti‐ CD38 monoclonal antibodies. British Journal of Haematology, 205(6), 2262-2267. https://doi.org/10.1111/bjh.19784
Vancouver
Zabaleta A, Blanco L, Kim PS, Bisht K, Wang H, Van de Velde H, et al. A CD38 / CD3xCD28 trispecific T‐cell engager as a potentially active agent in multiple myeloma patients relapsed and/or refractory to anti‐ CD38 monoclonal antibodies. British Journal of Haematology. 2024;205(6):2262-2267. doi:10.1111/bjh.19784
BibTeX
@article{Zabaleta2024,
author = {Zabaleta, Aintzane and Blanco, Laura and Kim, Peter S and Bisht, Kamlesh and Wang, Hongfang and Van de Velde, Helgi and Lasa, Marta and Tamariz-Amador, Luis-Esteban and Rodriguez-Otero, Paula and San-Miguel, Jesús and Paiva, Bruno and Martín-Sánchez, Esperanza},
title = {A CD38 / CD3xCD28 trispecific T‐cell engager as a potentially active agent in multiple myeloma patients relapsed and/or refractory to anti‐ CD38 monoclonal antibodies},
journal = {British Journal of Haematology},
year = {2024},
volume = {205},
number = {6},
pages = {2262--2267},
doi = {10.1111/bjh.19784}
}
EUVIMED